MarketsandMarkets

Biomarker and Companion Diagnostics Conference

3 - 4 October 2019

Radisson Blu Edwardian, Grafton Hotel, London

5 +

Sessions

20+

Speakers

150 +

Attendees

10+

Networking Hours

Redefining clinical stage biomarker strategies for a successful CDx commercialization

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.
Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.
Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

WHAT TO EXPECT

Clinical Biomarker Identification & Qualification

Biomarker and Personalized Medicine

Commercializing Biomarker in Therapeutic and Companion Diagnostic Applications

 

  • Clinical biomarker identification and qualification 
  • Biomarkers and personalized medicine 
  • Assay development and validation
  • NGS and novel technologies in biomarker discovery
  • Commercialization of biomarkers in therapeutic and CDx applications

  • Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

  • Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairman

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

08:55 - 09:00

Keynote Presentation: Biomarker Immunossays in multiplex and their Application in Preclinical and Clinical Research

Thomas Joos

Thomas Joos, Deputy Managing Director, University of Tübingen

09:00 - 09:30

CLINICAL BIOMARKER IDENTIFICATION & QUALIFICATION

Biosensing and imaging with upconversion nanoparticles

Prof. Gin Jose

Prof. Gin Jose, Chair in Functional Materials, University of Leeds

09:30 - 10:00

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Illip Burmester, Ph.D.

Illip Burmester, Ph.D. , Scientific Sales Support Europe, Proteome Sciences

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:20

Quantitative Methods towards Actionable Biomarkers

Dr. Richardus Vonk

Dr. Richardus Vonk, VP, Head Oncology Statistics and Data Management, Bayer AG

11:20 - 11:50

High Definition Multiplexing for Biomarker Strategies and CDx Development

Louis Levy

Louis Levy, Director of Corporate and Business Development, Ultivue

11:50 - 12:20

Considerations for developing clinical Biomarker strategies in immuno-oncology

Stephanie Traub

Stephanie Traub, Associate Director, Translational Biomarkers & Bioanalysis, UCB

12:20 - 12:50

Validation of a digital pathology workflow: a lab experience.

Shanon Seger

Shanon Seger, Scientist - Imaging Specialist, Roche

12:50 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 14:20

BIOMARKERS & PERSONALIZED MEDICINE

Circulating biomarkers- the bright future in cancer diagnosis and precision medicine

Yong-Jie Lu

Yong-Jie Lu , Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)

14:20 - 14:50

Digital Biomarkers transforming drug development and precision health practices

Dan Sikkema

Dan Sikkema, Vice President, Quanterix

14:50 - 15:20

A Novel technique to analyse biomarkers for critical diseases

Dr. Sikha Saha

Dr. Sikha Saha, Associate Professor of Cardiovascular and Cerebrovascular Medicine, University of Leeds

15:20 - 15:50

Exosome Based Liquid Biopsies

Mikkel Noerholm

Mikkel Noerholm, VP of Product Development, Exosome Diagnostics

15:50 - 16:20

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

16:20 - 17:10

Imaging Biomarkers of breast cancer risk

Dr. Susan Astley

Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester

17:10 - 17:40

Biomarkers and personalized medicine

Dr. Bernadett Szabados

Dr. Bernadett Szabados, Clinical Research Associate, Barts Cancer Institute

17:40 - 18:10

Closing Remarks from the Chairman

18:10 - 18:15

Drinks Reception & Networking

18:15 - 19:00

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairman

Yong-Jie Lu

Yong-Jie Lu , Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)

08:55 - 09:00

Keynote Presentation: Functional Proteomic Biomarkers

Peter Parker

Peter Parker, Director of the CRUK KHP Centre and Professor of Cancer Cell Biology, KCL

09:00 - 09:30

COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND COMPANION DIAGNOSTIC APPLICATIONS

Pathway Biomarkers for Precision Medicine

Dr. Paul J. Skipp

Dr. Paul J. Skipp, Associate Professor/Centre Director, Centre for Proteomic Research, University of Southampton

09:30 - 10:00

Implementing Immunosequencing as New Molecular Biomarkers of Response to Immunotherapy

Ned Sherry

Ned Sherry, Manager, Research and Business Development, Adaptive Biotechnologies

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:20

Precision Medicine in Hematology: Measurable residual disease hope, hype or both?

Celine Pallaud

Celine Pallaud, Executive Director, Oncology Precision Medicine Hematology DA Lead, Novartis

11:20 - 11:50

Development of an integrated platform for biomarker and drug target discovery using proteomics

Tony Whetton

Tony Whetton, Professor of Cancer Cell Biology, University of Manchester

11:50 - 12:20

The clinical and regulatory development of a Trastuzumab biosimilar: the story of CT-P6

Justin Stebbing

Justin Stebbing, Professor of Cancer Medicine and Oncology, Imperial College London

12:20 - 12:50

Longitudinal and Network Serum Biomarker Models for Early Detection of Ovarian Cancer

John Timms

John Timms, Reader in Cancer Proteomics, University College London

12:50 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 14:20

Functional Biomarkers of DNA repair

Nicola Curtin

Nicola Curtin, Professor of Experimental Therapeutics, Newcastle University

14:20 - 14:50

Biomarkers for early Pancreatic Cancer detection

Eithne Costello-Goldring

Eithne Costello-Goldring, Professor of Molecular Oncology, University of Liverpool

14:50 - 15:20

Biomarker commercialization support tool for researchers

Valerie Daussin Laurent

Valerie Daussin Laurent, , Business Developer, Aalborg University Hospital and Project Leader, BIC Consortium

15:20 - 15:50

Novel serum biomarkers for fatty liver disease

Dr. Bevin Gangadharan

Dr. Bevin Gangadharan, Research Associate, University of Oxford

15:50 - 16:20

Closing remarks from the chairman

16:20 - 16:25

CONFERENCE SPEAKERS

ADVISORS

Stephanie Traub

Stephanie Traub

Associate Director, Translational Biomarkers & Bioanalysis, UCB

Thomas Joos

Thomas Joos

Deputy Managing Director, University of Tübingen

SPEAKERS

Shailendra Singh (Shelly)

Shailendra Singh (Shelly)

Board Member, MarketsandMarkets

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Stephanie Traub

Stephanie Traub

Associate Director, Translational Biomarkers & Bioanalysis, UCB

Thomas Joos

Thomas Joos

Deputy Managing Director, University of Tübingen

Dan Sikkema

Dan Sikkema

Vice President, Quanterix

Peter Parker

Peter Parker

Director of the CRUK KHP Centre and Professor of Cancer Cell Biology, KCL

Dr. Richardus Vonk

Dr. Richardus Vonk

VP, Head Oncology Statistics and Data Management, Bayer AG

Yong-Jie Lu

Yong-Jie Lu

Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)

Tony Whetton

Tony Whetton

Professor of Cancer Cell Biology, University of Manchester

Shanon Seger

Shanon Seger

Scientist - Imaging Specialist, Roche

Louis Levy

Louis Levy

Director of Corporate and Business Development, Ultivue

Dr. Bevin Gangadharan

Dr. Bevin Gangadharan

Research Associate, University of Oxford

Nicola Curtin

Nicola Curtin

Professor of Experimental Therapeutics, Newcastle University

Dr. Paul J. Skipp

Dr. Paul J. Skipp

Associate Professor/Centre Director, Centre for Proteomic Research, University of Southampton

Dr. Sikha Saha

Dr. Sikha Saha

Associate Professor of Cardiovascular and Cerebrovascular Medicine, University of Leeds

Dr. Susan Astley

Dr. Susan Astley

Division of Informatics, Imaging & Data Sciences, University of Manchester

Pierre Arsene

Pierre Arsene

Co-Founder & CEO, Mursla

Celine Pallaud

Celine Pallaud

Executive Director, Oncology Precision Medicine Hematology DA Lead, Novartis

Eithne Costello-Goldring

Eithne Costello-Goldring

Professor of Molecular Oncology, University of Liverpool

John Timms

John Timms

Reader in Cancer Proteomics, University College London

Dr. Bernadett Szabados

Dr. Bernadett Szabados

Clinical Research Associate, Barts Cancer Institute

Prof. Gin Jose

Prof. Gin Jose

Chair in Functional Materials, University of Leeds

Ned Sherry

Ned Sherry

Manager, Research and Business Development, Adaptive Biotechnologies

Justin Stebbing

Justin Stebbing

Professor of Cancer Medicine and Oncology, Imperial College London

Mikkel Noerholm

Mikkel Noerholm

VP of Product Development, Exosome Diagnostics

Valerie Daussin Laurent

Valerie Daussin Laurent

, Business Developer, Aalborg University Hospital and Project Leader, BIC Consortium

ENQUIRE NOW

SPONSORS

Proteome Sciences
Quanterix
Adaptive Biotechnologies
Tissue Solutions
 Olink Proteomics
Invivoscribe
Intertek
Myriad RBM
Mursla
Ultivue
Bio-Techne
BioLegend
BIC Biomarker commercialization

PARTNERS

LOCATION

Venue

Radisson Blu Edwardian, Grafton Hotel, London

PAST EVENT GALLERY